Becton, Dickinson and Company (NYSE:BDX) Plans Quarterly Dividend of $1.06

Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Thursday, November 5th. Shareholders of record on Thursday, December 10th will be paid a dividend of $1.06 per share by the medical instruments supplier on Thursday, December 31st. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Thursday, December 10th. This is a 1.0% increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.05.

Becton, Dickinson and Company has raised its dividend payment by an average of 0.1% per year over the last three years and has raised its dividend annually for the last 53 consecutive years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Becton, Dickinson and Company to earn $13.24 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 31.7%.

Becton, Dickinson and Company Trading Up 1.8%

BDX traded up $3.86 during trading on Thursday, reaching $213.05. 3,990,398 shares of the company’s stock were exchanged, compared to its average volume of 2,439,275. The company’s fifty day moving average price is $187.23 and its 200-day moving average price is $170.20. The firm has a market capitalization of $58.70 billion, a PE ratio of 64.17, a P/E/G ratio of 13.36 and a beta of 0.22. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $214.78. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. During the same quarter in the prior year, the business posted $3.96 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.